Clinical Trial: Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura
Study Status: Completed
Recruit Status: Unknown status
Study Type: Interventional
Official Title: Phase II Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura
Brief Summary: This study is designed to evaluate the efficacy and safety of single agent Doxil in the treatment of patients with refractory ITP (Idiopathic Thrombocytopenic Purpura).
Detailed Summary: Eligible patients will receive Doxil 20 mg/m2 IV over 1 hour every 2 weeks. Treatment will be continued for 1 course beyond return of the platelet count to normal with a maximum of 18 courses.
Sponsor: Hematology and Oncology Specialists
Current Primary Outcome: the primary outcome would be a platelet response, with a return of platelet count to normal
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Hematology and Oncology Specialists
Dates:
Date Received: April 11, 2005
Date Started: September 2001
Date Completion: April 2005
Last Updated: June 23, 2005
Last Verified: April 2005